Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History HRTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics HRTX

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Heron Therapeuti

HRTX
Current price
2.11 USD +0.13 USD (+6.57%)
Last closed 2.00 USD
ISIN US4277461020
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 305 128 000 USD
Yield for 12 month -33.65 %
1Y
3Y
5Y
10Y
15Y
HRTX
21.11.2021 - 28.11.2021

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina. Address: 100 Regency Forest Drive, Cary, NC, United States, 27518

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

6.25 USD

P/E ratio

Dividend Yield

Financials HRTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures HRTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+144 285 000 USD

Last Year

+192 149 000 USD

Current Quarter

+38 903 000 USD

Last Quarter

+40 781 000 USD

Current Year

+105 637 000 USD

Last Year

+61 939 000 USD

Current Quarter

+30 446 000 USD

Last Quarter

+30 553 000 USD
EBITDA -1 222 000 USD
Operating Margin TTM 8.11 %
Price to Earnings
Return On Assets TTM -0.99 %
PEG Ratio -0.18
Return On Equity TTM -2 408.88 %
Wall Street Target Price 6.25 USD
Revenue TTM 148 518 000 USD
Book Value -0.19 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 12.20 %
Dividend Yield
Gross Profit TTM 95 503 000 USD
Earnings per share -0.050 USD
Diluted Eps TTM -0.050 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin -5.24 %

Stock Valuation HRTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 2.91
Price Sales TTM 2.05
Enterprise Value EBITDA 156.53
Price Book MRQ 12.60

Technical indicators HRTX

For 52 weeks

1.04 USD 3.73 USD
50 Day MA 2.03 USD
Shares Short Prior Month 34 412 865
200 Day MA 1.86 USD
Short Ratio 16.82
Shares Short 33 960 047
Short Percent 28.94 %